Active Pharmaceutical Ingredient For Cancer Market Report: Information by Type (Tyrosine Kinase Inhibitor (Tinib), Proteasome Inhibitors (Parib), BRAF Kinase Inhibitors (Rafenib), Phosphatidylinositol 3-Kinase Inhibitors (Lisib), SMO Receptor Antagonists (Degib), Cyclin Dependent Kinase Inhibitors (Ciclib) and others), Indications (Blood Cancer, Skin Cancer, Lung Cancer, Breast Cancer, Pancreas Cancer, Others), End User (Pharmaceutical Companies, Research Organizations, Others) and Region (Americas, Europe, Asia-Pacific and Middle East ...
ID: MRFR/HC/6828-HCR | August 2022 | Region: Global | 164 Pages
Table of Contents:
Chapter 1. Executive Summary
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions
2.4 Limitations
Chapter 3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
Chapter 4. Market Dynamics
4.1 Overview
4.2 Drivers
4.3 Restraints
4.4 Opportunities
4.5 Pipeline Analysis
4.5 Macroeconomic Indicators
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Opportunities
Chapter 6. Global Active Pharmaceutical Ingredient for Cancer Market, by Type
6.1 Overview
6.2 Tyrosine kinase inhibitor (Tinib)
6.2.1 Ponatinib
6.2.2 Brigatinib
6.2.3 Ruxolitinib
6.2.4 Erlotinib
6.2.5 Alectinib
6.2.6 Cobimetinib
6.2.7 Neratinib
6.2.8 Osimertinib
6.2.9 Acalabrutinib
6.2.10 Bosutinib
6.2.11 Crizotinib
6.2.12 Axitinib
6.2.13 Sunitinib
6.2.14 Ceritinib
6.2.15 Imatinib
6.2.16 Lapatinib
6.2.17 Afatinib
6.2.18 Cabozantinib
6.2.19 Dasatinib
6.2.20 Ibrutinib
6.2.21 Lenvatinib
6.2.22 Gefitinib
6.2.23 Others
6.3 Proteasome Inhibitors (Parib)
6.3.1 Olaparib
6.3.2 Rucaparib
6.3.3 Niraparib
6.4 BRAF Kinase Inhibitors (rafenib)
6.4.1 Sorafenib
6.4.2 Regorafenib
6.4.3 Vemurafenib
6.4.4 Dabrafenib
6.4.5 Enasidenib
6.4.6 Others
6.5 Phosphatidylinositol 3-kinase Inhibitors (Lisib)
6.5.1 Idelalisib
6.5.2 Copanlisib
6.6 SMO Receptor Antagonists (Degib)
6.6.1 Sonidegib
6.6.2 Vismodegib
6.7 Cyclin Dependent Kinase Inhibitors (Ciclib)
6.7.1 Palbociclib
6.7.2 Ribociclib
6.7.3 Abemaciclib
6.8 Others
Chapter 7. Global Active Pharmaceutical Ingredient for Cancer Market, by Indication
7.1 Overview
7.2 Blood Cancer
7.3 Skin Cancer
7.4 Lungs Cancer
7.5 Breasts Cancer
7.6 Pancreas Cancer
7.7 Others
Chapter 8. Global Active Pharmaceutical Ingredient for Cancer Market, by End User
8.1 Overview
8.2 Pharmaceutical Companies
8.3 Research Organizations
8.4 Others
Chapter 10. Global Active Pharmaceutical Ingredient for Cancer Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Key Development & Strategies
Chapter 12 Company Profiles
12.1 AbbVie
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 Pfizer Inc.
12.3 Boehringer Ingelheim International GmbH
12.4 AstraZeneca
12.5 Novartis AG.
12.6 F. Hoffmann-La Roche AG
12.7 Bayer AG
12.8 Bristol-Myers Squibb Company
12.9 Eisai Co., Ltd
12.10 Johnson & Johnson
12.11 Merck Sharp & Dohme Corp.
12.12 Amgen Inc
12.13 Others
Chapter 13 Appendix
LIST OF TABLES
TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SYNOPSIS, 2020-2027
TABLE 2. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)
TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 7. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 8. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 9. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 10. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 11. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 12. US: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 13. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 14. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 15. CANADA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 16. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 17. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 18. LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 19. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 20. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 21. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 22. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 23. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 24. WESTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 25. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 26. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 27. EASTERN EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 28. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 29. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 31. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 32. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY INDICATIONS, 2020-2027 (USD MILLION)
TABLE 33. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1. RESEARCH PROCESS
FIGURE 2. SEGMENTATION FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET
FIGURE 3. MARKET DYNAMICS FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET
FIGURE 4. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY TYPE, 2020
FIGURE 5. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY INDICATIONS, 2020
FIGURE 6. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY END USER, 2020
FIGURE 7. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY REGION, 2020
FIGURE 8. NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020
FIGURE 9. EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020
FIGURE 10. ASIA-PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY COUNTRY, 2020
FIGURE 11. MIDDLE EAST & AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET SHARE, BY REGION, 2020
FIGURE 12. ACTIVE PHARMACEUTICAL INGREDIENT FOR CANCER MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 13. ABBVIE: KEY FINANCIALS
FIGURE 14. ABBVIE: SEGMENTAL REVENUE
FIGURE 15. ABBVIE: GEOGRAPHICAL REVENUE
FIGURE 16. PFIZER INC: KEY FINANCIALS
FIGURE 17. PFIZER INC: SEGMENTAL REVENUE
FIGURE 18. PFIZER INC: GEOGRAPHICAL REVENUE
FIGURE 19. PFIZER INC: KEY FINANCIALS
FIGURE 20. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SEGMENTAL REVENUE
FIGURE 21. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: GEOGRAPHICAL REVENUE
FIGURE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY FINANCIALS
FIGURE 23. ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 24. ASTRAZENECA: GEOGRAPHICAL REVENUE
FIGURE 25. ASTRAZENECA: KEY FINANCIALS
FIGURE 26. NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 27. NOVARTIS AG: GEOGRAPHICAL REVENUE
FIGURE 28. NOVARTIS AG.: KEY FINANCIALS
FIGURE 29. F. HOFFMANN-LA ROCHE AG.: SEGMENTAL REVENUE
FIGURE 30. F. HOFFMANN-LA ROCHE AG.: GEOGRAPHICAL REVENUE
FIGURE 31. F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS
FIGURE 32. BAYER AG: SEGMENTAL REVENUE
FIGURE 33. BAYER AG: GEOGRAPHICAL REVENUE
FIGURE 34. BAYER AG: KEY FINANCIALS
FIGURE 35. BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 36. BRISTOL-MYERS SQUIBB COMPANY: GEOGRAPHICAL REVENUE
FIGURE 37. BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
FIGURE 38. EISAI CO., LTD: SEGMENTAL REVENUE
FIGURE 39. EISAI CO., LTD: GEOGRAPHICAL REVENUE
FIGURE 40. EISAI CO., LTD: KEY FINANCIALS
FIGURE 41. JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 42. JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE
FIGURE 43. JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 44. MERCK SHARP & DOHME CORP.: SEGMENTAL REVENUE
FIGURE 45. MERCK SHARP & DOHME CORP.: GEOGRAPHICAL REVENUE
FIGURE 46. MERCK SHARP & DOHME CORP.: KEY FINANCIALS
FIGURE 47. AMGEN INC: SEGMENTAL REVENUE
FIGURE 48. AMGEN INC: GEOGRAPHICAL REVENUE
FIGURE 49. AMGEN INC: KEY FINANCIALS
Speak to Analyst
Request a Free Sample
Active Pharmaceutical Ingredient for Cancer Market Synopsis
Active Pharmaceutical Ingredient (API) for Cancer Market is expected to register a CAGR of 8.1% and is anticipated to reach USD 34,300.00 Million by 2025. API for cancer market, including conventional syringes, needle-free injectors, and auto and pen injectors have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The market for API for cancer has witnessed continuously rising R&D. As a result, the active pharmaceutical ingredient for cancer market is fragmented into various advanced products as per the molecules. Following the illustrated course, it is projected that increasing prevalence of cancer, growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs drives the market growth. However, side effects associated with the medication are estimated to restrain the market growth during the forecast period.
Active Pharmaceutical Ingredient for Cancer Market Dynamics
The active pharmaceutical ingredient for cancer market is driven by increasing prevalence of cancer drives the market growth. According to the statistical report published by the World Health Organization (WHO) in 2018, around 18.1 million new cases of cancers were estimated reported worldwide. This indicates a potential for growth in the global API for cancer market.
The other factors that are driving the global API for cancer market are growing technologies for treatments of various types of cancer, and rising FDA approvals of anticancer drugs, growing demand for newly developed small molecules drugs, and others.
Global Active Pharmaceutical Ingredient for Cancer Market Size, by Indication, 2018 & 2025 (USD Million) 
Source: MRFR Analysis
Active Pharmaceutical Ingredient for Cancer Market Segmentation
The global API for cancer market has been segmented into by type, indications, and end users.
Based on type it is segmented into tinib, parib, rafenib, lisib, degib, ciclib, and others
Based on indication, it is segmented into blood cancer, skin cancer, lungs cancer, breasts cancer, pancreas cancer, others.
Based on end user, the market is segmented into pharmaceutical companies, research organizations, others.
Active Pharmaceutical Ingredient for Cancer Market Key Players
The prominent players in the global API for cancer market are AbbVie, Pfizer Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Novartis AG., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., and others.
Global Active Pharmaceutical Ingredient for Cancer Market Share, by Region, 2018 (%) 
Source: MRFR Analysis
Active Pharmaceutical Ingredient for Cancer Market Regional Analysis
The global API for cancer market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is anticipated to dominate the global API for cancer market owing to the rising awareness about the condition and high healthcare expenditure. The Americas is expected to reach USD 34,300.00 million by 2025 at a CAGR of 8.1% from 2018 to 2025. The Americas region accounted largest regional market owing to the growing biotechnology industry, the growing prevalence of cancer, and a highly developed healthcare sector.
Europe accounted for the second-largest market share in 2018 due to extensive R&D for healthcare, increasing funding, and growing adoption of the technology within the region.
On the other hand, the Middle East and Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.
Key Updates
- In May 2019, Eli Lilly and Company received US Food and Drug Administration approval for its drug Cyramza (ramucirumab) a human VEGFR2 antagonist. It is a recombinant molecule of the human IgG1 monoclonal antibody.
- In April 2019 Johnson & Johnson received US Food and Drug Administration approval for product Balversa (erdafitinib), oral fibroblast growth factor receptor (FGFR) kinase inhibitor.
Market Segmentation
Global Active Pharmaceutical Ingredient for Cancer Market, by Type
- Tyrosine Kinase Inhibitor (Tinib)
- Ponatinib
- Brigatinib
- Ruxolitinib
- Erlotinib
- Alectinib
- Cobimetinib
- Neratinib
- Osimertinib
- Acalabrutinib
- Bosutinib
- Crizotinib
- Axitinib
- Sunitinib
- Ceritinib
- Imatinib
- Lapatinib
- Afatinib
- Cabozantinib
- Dasatinib
- Ibrutinib
- Lenvatinib
- Gefitinib
- Others
- Proteasome Inhibitors (Parib)
- Olaparib
- Rucaparib
- Niraparib
- BRAF Kinase Inhibitors (rafenib)
- Sorafenib
- Regorafenib
- Vemurafenib
- Dabrafenib
- Enasidenib
- Others
- Phosphatidylinositol 3-Kinase Inhibitors (Lisib)
- Idelalisib
- Copanlisib
- SMO Receptor Antagonists (Degib)
- Sonidegib
- Vismodegib
- Cyclin Dependent Kinase Inhibitors (Ciclib)
- Palbociclib
- Ribociclib
- Abemaciclib
- Others
Global API for Cancer Market, by Indication
- Blood Cancer
- Skin Cancer
- Lungs Cancer
- Breasts Cancer
- Pancreas Cancer
- Others
Global Active Pharmaceutical Ingredient for Cancer Market, by End User
- Pharmaceutical Companies
- Research Organizations
- Others
Global Active Pharmaceutical Ingredient for Cancer Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Additional Companies
- Supply & Demand Analysis
Intended Audience
- Pharmaceutical Companies
- Hospitals and Clinics
- Regulatory Agencies
- Research Institutes
